ReviewMalaria journal2018
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency.
Review in Malaria journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 6 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Systematic review and individual patient data meta-analysis on glucose- 6 - phosphate dehydrogenase activities measured by a semi-quantitative handheld biosensor.Malaria journal · 2025Pooled it
- Pooled it
- Performance of quantitative point-of-care tests to measure G6PD activity: An individual participant data meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Population screening for glucose-6-phosphate dehydrogenase deficiency using quantitative point-of-care tests: a systematic review.Frontiers in genetics · 2023Pooled it
- Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.PLoS medicine · 2019Pooled it
- Pooled it
- Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.PLoS neglected tropical diseases · 2021Trial
- G6PD activity patterns and a stable adjusted male median derived from 16 years of clinical laboratory data.Blood research · 2026Article
- Integrated enzymatic and molecular diagnosis of G6PD deficiency: a one-year experience identifying five novel variants.Annals of hematology · 2026Article
- The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics-Based Clinical Guidelines.Clinical pharmacology and therapeutics · 2026Article
- Performance evaluation of an automated method for accurate identification of glucose-6-phosphate dehydrogenase deficiency on the BS-2800M analyzer.Malaria journal · 2026Article
- Quantifying phenylhydrazine-induced Heinz body formation in normal human erythrocytes by flow cytometry versus microscopy or spectrophotometry.Biology methods & protocols · 2026Article
- Tafenoquine lactation pharmacokinetics: a pilot study.Malaria journal · 2025Article
- Incidental Identification of Potentially Affected Individuals Through Expanded Carrier Screening During Preconception or Early Pregnancy.Prenatal diagnosis · 2025Article
- Integrated Phenotypic and Genotypic Approaches for Accurate Diagnosis of G6PD Deficiency: Implications for Drug Safety in Thailand.Pharmacology research & perspectives · 2025Article
- Improved genetic screening with zygosity detection through multiplex high-resolution melting curve analysis and biochemical characterisation for G6PD deficiency.Tropical medicine & international health : TM & IH · 2025Article
- Global, regional, and national burden of glucose-6-phosphate dehydrogenase (G6PD) deficiency from 1990 to 2021: a systematic analysis of the global burden of disease study 2021.Frontiers in genetics · 2025Article
- Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure.Malaria journal · 2024Review
- The effect of single low-dose primaquine treatment for uncomplicated Plasmodium falciparum malaria on haemoglobin levels in Ethiopia: a longitudinal cohort study.Malaria journal · 2024Observational
- Serum microRNAs as new biomarkers for detecting subclinical hemolysis in the nonacute phase of G6PD deficiency.Scientific reports · 2024Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
Abstract
Oxidative agents can cause acute haemolytic anaemia in persons with G6PD deficiency. Understanding the relationship between G6PD genotype and the phenotypic expression of the enzyme deficiency is necessary so that severe haemolysis can be avoided. The patterns of oxidative haemolysis have been well described in G6PD deficient hemizygous males and homozygous females; and haemolysis in the proportionally more numerous heterozygous females has been documented mainly following consumption of fava beans and more recently dapsone. It has long been known that 8-aminoquinolines, notably primaquine and tafenoquine, cause acute haemolysis in G6PD deficiency. To support wider use of primaquine in Plasmodium vivax elimination, more data are needed on the haemolytic consequences of 8-aminoquinolines in G6PD heterozygous females. Two recent studies (in 2017) have provided precisely such data; and the need has emerged for the development of point of care quantitative testing of G6PD activity. Another priority is exploring alternative 8-aminoquinoline dosing regimens that are practical and improve safety in G6PD deficient individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.